{"id":61962,"date":"2025-10-02T10:02:34","date_gmt":"2025-10-02T08:02:34","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\/"},"modified":"2025-10-02T10:02:34","modified_gmt":"2025-10-02T08:02:34","slug":"genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\/","title":{"rendered":"Genialis and Cleveland Clinic Collaborate to Develop AI-Powered Biomarkers that Improve Pancreatic Cancer Care"},"content":{"rendered":"
\n

\nThe program<\/i> aims to deliver better guidance for physicians and ultimately improve outcomes for pancreatic cancer patients.<\/i><\/p>\n

BOSTON–(BUSINESS WIRE)–#NGS<\/a>–Genialis, the RNA biomarker company, today announced a collaboration with Cleveland Clinic, one of the world\u2019s leading academic medical centers, to develop AI-powered tools that help doctors identify the most effective treatment options for patients with pancreatic ductal adenocarcinoma (PDAC), the most common and deadliest form of pancreatic cancer.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe collaboration leverages the Genialis\u2122 Supermodel, a foundation model built from one of the world\u2019s largest and most diverse RNA-sequencing datasets to create predictive biomarker algorithms. These tools aim to help clinicians identify the most effective therapies for individual PDAC patients, optimize treatment selection, and accelerate access to novel drug strategies.<\/p>\n

\nAddressing an Urgent Need<\/b><\/p>\n

\nPDAC is one of the most aggressive and lethal cancers, responsible for more than 90 percent, or over 50,000, of pancreatic cancer deaths annually in the United States alone1<\/sup>. Despite improved survivorship in some common cancers, the Cancer Research Institute cites2<\/sup> that the PDAC five-year relative survival rate remains around 9 percent, among the lowest across all cancer types.<\/p>\n

\nTogether, Genialis and Cleveland Clinic will work on testing Genialis Supermodel predictions across a range of therapies and combinations in the hospital\u2019s patient-derived organoid center to quickly validate and iterate on predictive algorithms.<\/p>\n

\n\u201cFor clinicians, time is critical. While standard therapies exist, we lack validated biomarkers to identify which patients are most likely to benefit from various treatment options,\u201d said Wen Wee Ma, MD, Director, Novel Cancer Therapeutics Center, Enterprise Vice Chair, Research Cleveland Clinic Cancer Institute. \u201cEmerging therapies, including KRAS inhibitors, offer new hope but require precise patient selection to achieve meaningful outcomes. Our goal is to bring practical, data-driven tools into the clinic that help us choose the best treatment paths for patients who currently have very few effective options.\u201d Dr. Ma will serve in an advisory capacity and may receive research funding and royalties.<\/p>\n

\nThe majority of PDAC cases harbors a KRAS mutation.3<\/sup><\/p>\n

\n\u201cThrough our work on biomarker algorithms for KRAS inhibitors, Genialis has already made a major investment in understanding the drivers of PDAC,\u201d said Rafael Rosengarten, Ph.D., CEO of Genialis. \u201cOur collaboration with Cleveland Clinic aims to extend these insights to give doctors and patients better tools to combat the disease. This is an important step toward truly data-driven, personalized care in one of the most pressing areas of unmet need.\u201d<\/p>\n

\nGenialis\u2122 krasID, powered by the Genialis Supermodel, is the first biomarker algorithm that can predict patient response and clinical benefit to KRAS inhibitors (KRASi) across tissue histology and mutation type. Genialis krasID can help guide drug development from early preclinical phases (e.g., compound\/MOA differentiation and selection), to clinical trials (e.g., patient selection for clinical trials and identification of combination therapies), to market access and clinical care (e.g., development of CDx and as a clinical decision tool).<\/p>\n

\nAbout Genialis<\/b><\/p>\n

\nGenialis is creating a world where healthcare delivers the best possible outcomes for patients, families, and communities. As the RNA biomarker company, Genialis develops clinically actionable biomarkers informed by the world\u2019s most diverse cancer data to guide precision medicine. Partnering with leading pharmaceutical and diagnostic companies, Genialis is transforming medicine through data. Learn more at www.genialis.com<\/a>.<\/p>\n\n\n\n\n\n
____________________<\/td>\n<\/tr>\n
\n

\n1 <\/sup>https:\/\/www.cancerresearch.org\/immunotherapy-by-cancer-type\/pancreatic-cancer<\/a><\/p>\n<\/td>\n<\/tr>\n

\n

\n2<\/sup> https:\/\/www.cancerresearch.org\/immunotherapy-by-cancer-type\/pancreatic-cancer<\/a><\/p>\n<\/td>\n<\/tr>\n

\n

\n3 <\/sup>https:\/\/www.nature.com\/articles\/s41591-024-03362-3<\/a><\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n\u00a0<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contacts<\/b>
Andrea Vuturo
\n
Vuturo Group for Genialis
\n
andrea@vuturo.com<\/a>
+1 (415) 689-8414<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The program aims to deliver better guidance for physicians and ultimately improve outcomes for pancreatic cancer patients. BOSTON–(BUSINESS WIRE)–#NGS–Genialis, the RNA biomarker company, today announced a collaboration with Cleveland Clinic, one of the world\u2019s leading academic medical centers, to develop AI-powered tools that help doctors identify the most effective treatment options for patients with pancreatic … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61962","6":"format-standard","7":"category-industry"},"yoast_head":"\nGenialis and Cleveland Clinic Collaborate to Develop AI-Powered Biomarkers that Improve Pancreatic Cancer Care - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genialis and Cleveland Clinic Collaborate to Develop AI-Powered Biomarkers that Improve Pancreatic Cancer Care - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The program aims to deliver better guidance for physicians and ultimately improve outcomes for pancreatic cancer patients. BOSTON–(BUSINESS WIRE)–#NGS–Genialis, the RNA biomarker company, today announced a collaboration with Cleveland Clinic, one of the world\u2019s leading academic medical centers, to develop AI-powered tools that help doctors identify the most effective treatment options for patients with pancreatic ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-02T08:02:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251002765516\/en\/2597266\/22\/Genialis_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Genialis and Cleveland Clinic Collaborate to Develop AI-Powered Biomarkers that Improve Pancreatic Cancer Care\",\"datePublished\":\"2025-10-02T08:02:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\\\/\"},\"wordCount\":590,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251002765516\\\/en\\\/2597266\\\/22\\\/Genialis_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\\\/\",\"name\":\"Genialis and Cleveland Clinic Collaborate to Develop AI-Powered Biomarkers that Improve Pancreatic Cancer Care - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251002765516\\\/en\\\/2597266\\\/22\\\/Genialis_logo.jpg\",\"datePublished\":\"2025-10-02T08:02:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251002765516\\\/en\\\/2597266\\\/22\\\/Genialis_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251002765516\\\/en\\\/2597266\\\/22\\\/Genialis_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genialis and Cleveland Clinic Collaborate to Develop AI-Powered Biomarkers that Improve Pancreatic Cancer Care\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genialis and Cleveland Clinic Collaborate to Develop AI-Powered Biomarkers that Improve Pancreatic Cancer Care - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\/","og_locale":"en_US","og_type":"article","og_title":"Genialis and Cleveland Clinic Collaborate to Develop AI-Powered Biomarkers that Improve Pancreatic Cancer Care - Pharma Trend","og_description":"The program aims to deliver better guidance for physicians and ultimately improve outcomes for pancreatic cancer patients. BOSTON–(BUSINESS WIRE)–#NGS–Genialis, the RNA biomarker company, today announced a collaboration with Cleveland Clinic, one of the world\u2019s leading academic medical centers, to develop AI-powered tools that help doctors identify the most effective treatment options for patients with pancreatic ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\/","og_site_name":"Pharma Trend","article_published_time":"2025-10-02T08:02:34+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251002765516\/en\/2597266\/22\/Genialis_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Genialis and Cleveland Clinic Collaborate to Develop AI-Powered Biomarkers that Improve Pancreatic Cancer Care","datePublished":"2025-10-02T08:02:34+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\/"},"wordCount":590,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251002765516\/en\/2597266\/22\/Genialis_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\/","url":"https:\/\/pharma-trend.com\/en\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\/","name":"Genialis and Cleveland Clinic Collaborate to Develop AI-Powered Biomarkers that Improve Pancreatic Cancer Care - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251002765516\/en\/2597266\/22\/Genialis_logo.jpg","datePublished":"2025-10-02T08:02:34+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251002765516\/en\/2597266\/22\/Genialis_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251002765516\/en\/2597266\/22\/Genialis_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/genialis-and-cleveland-clinic-collaborate-to-develop-ai-powered-biomarkers-that-improve-pancreatic-cancer-care\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Genialis and Cleveland Clinic Collaborate to Develop AI-Powered Biomarkers that Improve Pancreatic Cancer Care"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61962"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61962\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61962"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61962"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}